KAI1, a metastasis suppressor gene of prostate cancer, is located on human chromosome 11p11.2. Down-regulation of KAI1 mRNA during tumor progression and metastasis has been reported for several kinds of cancer, but the mechanism of this down-regulation is not known. In the present study, our aim was to ascertain the relationship between down-regulation of KAI1 mRNA expression and KAI1 gene alterations in lung cancer. Forty-nine cases of adenocarcinoma of the lung were studied by reverse-transcriptase polymerase chain reaction ( 
Lung cancer was the most lethal malignant neoplasm in Japanese males in 1993, 1) and more than 33,000 male persons die each year from lung cancer. The most serious problem in the treatment of lung cancer is the poor prognosis after surgery, even when the disease stage is early; the 5-year survival rates are 67% for stage IA and 57% for stage IB.
2) These data suggest that microinvasion or micrometastasis exists at the time of surgery and can not be controlled, so it is necessary to clarify the mechanism of invasion or metastasis.
Recently the KAI1 gene (human chromosome 11p11.2) was identified as a metastasis suppressor gene of prostate cancer; decreased KAI1 mRNA expression is involved in the progression of prostate cancers with metastatic ability.
3) KAI1 protein is identical to CD82, consists of 267 amino acids, and is a member of the transmembrane 4 superfamily, which includes CD9, 4) CD37, 5) CD53, 6) CD63 7) and CD81. 8) Members of this family are cell membrane glycoproteins containing a type III integral membrane structure with four transmembrane domains.
9) The KAI1 protein also has one large extracellular hydrophilic domain with three potential N-glycosylation sites. These sites are consistent with the suggested role of metastasis suppression. 10) Reports about many cancer types, including lung cancer, 11, 12) pancreatic cancer, 13) breast cancer, 14) bladder cancer 15) and colon cancer, 16) have pointed out that downregulation of KAI1 mRNA is related to tumor progression, but it is not clear whether this down-regulation involves DNA alterations of the KAI1 region or not. In non-small cell lung cancer, low expression of KAI1 mRNA and protein correlates with a poor prognosis, 11, 12) but this correlation is significant only for adenocarcinoma and not for squamous cell carcinoma, so it seems that degrees of expression of KAI1 mRNA and protein have different significance with regard to invasion or metastasis of carcinoma cells between these two histological types, although the reason for this is unclear.
The aim of the present study was to clarify the relationship between down-regulation of KAI1 mRNA and the metastatic ability of lung adenocarcinomas, as well as to examine whether its down-regulation is associated with DNA alterations. Tissue samples One-half of each freshly resected tumor tissue had been frozen in OCT (optimal cutting temperature) compound (Miles Laboratories, Elkhart, IN) at −20°C at the time of surgery. At that time serial frozen sections with 5 µm thick had been cut on a cryostat and placed on 3-aminopropyl triethoxysilane (APS)-coated glass slides before storage at −80°C. The histological types of the carcinomas were confirmed by two pathologists independently using representative specimens of the tumors stained with hematoxylin and eosin. The other half of each tumor and its adjacent non-cancerous lung tissue, which had been stored whole at −80°C, were used for reverse-transcriptase polymerase chain reaction (RT-PCR) and microsatellite DNA analyses. RT-PCR Total RNA was isolated from each tumor specimen and from 12 paired specimens of non-cancerous lung tissue by acid-guanidinium-phenol-chloroform extraction. Then the total RNA (1 µg from each specimen) was reverse transcribed to obtain cDNAs in a 20-µl reaction mixture containing 1.2 µM oligo(dT) 18 2 , and 2 units of Taq polymerase (Ampli-Taq Gold; Perkin-Elmer, Foster City, CA) using an automated temperature control system (PC-800; Astec, Fukuoka). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) amplification was used as an internal control. To obtain reproducible quantitative data from the RT-PCR assay we chose the number of amplification cycles that gave linear amplification of the KAI1 and GAPDH cDNAs. The PCR conditions for the KAI1 and GAPDH cDNAs were 30 or 22 cycles respectively of denaturation at 94°C for 45 s, annealing at 62°C (KAI1 cDNA) or 60°C (GAPDH cDNA) for 45 s, and extension at 72°C for 120 s. The PCR products were separated by electrophoresis on a 2% agarose gel and stained with 0.2% ethidium bromide. The intensity of each band was evaluated by a CCD (charge-coupled device) image sensor (Densitograph AE-6900-F; Atto, Tokyo) under UV illumination. Negative control reactions without cDNA were carried out for each primer set and no product was detected (data not shown).
MATERIALS AND METHODS

Clinical and pathological characteristics
The primer sequences for KAI1 3) were 5′-AGTCCT-CCCTGCTGCTGTGTG-3′ (sense) and 5′-TCAGTCAG-GGTGGGCAAGAGG-3′ (antisense). This primer pair amplifies a 1031-bp fragment (nucleotides 65-1095). The primer sequences for GAPDH were 5′-CTCAGACAC-CATGGGGAAGGTGA-3′ (sense) and 5′-ATGATCTTG-AGGCTGTTGTCATA-3′ (antisense). Specimen classification based on mRNA levels Here the KAI1 mRNA level is presented as the density of the KAI1 cDNA band divided by that of the GAPDH band in the same gel. All of the non-cancerous lung tissues we examined had higher KAI1 mRNA levels than the tumor tissues and it has been shown previously, by northern blot analysis, that lung tissue expresses more KAI1 mRNA than any other human tissue.
3) So we concluded that KAI1 mRNA was conserved in our non-cancerous lung tissue specimens and we used the mean KAI1 mRNA level of the non-cancerous lung tissues as a control value. The level of KAI1 mRNA in each tumor was expressed relative to this control value. Ratios over 0.4 were considered to indicate conserved KAI1 mRNA expression, whereas ratios less than 0.4 were considered to indicate reduced KAI1 mRNA expression in the tumor. Immunohistochemical analysis The archival frozen sections were fixed in acetone at −20°C for 7 min and then in 4% paraformaldehyde at 4°C for 7 min. Staining was performed by the avidin-biotin-peroxidase complex method using a commercial kit (Histofine SAB-PO kit; Nichirei, Tokyo). To inhibit endogenous peroxidase activity, the sections were incubated at room temperature for 30 min in 0.3% H 2 O 2 in absolute methanol. Incubation with the anti- KAI1 rabbit polyclonal antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) was done at 4°C overnight. The sections were counterstained with hematoxylin. In the negative control, the anti-KAI1 antibody was replaced with phosphate-buffered saline (PBS). Specimen classification based on protein levels KAI1 protein was expressed on the cell membrane or in the cytoplasm of various cell types. Besides the adenocarcinoma cells, bronchial and bronchiolar epithelial cells and alveolar cells most clearly expressed KAI1 (Fig. 1) , whereas vascular endothelial cells, smooth muscle cells of the vascular wall and fibroblasts showed uneven expression. When the staining intensity of the adenocarcinoma cells was similar to or stronger than that of the non-cancerous bronchiolar epithelial or alveolar cells, cellular KAI1 protein expression was considered to be positive, otherwise it was considered to be negative. Moreover, when the frequency of KAI1-positive cells was over 50% in a tumor specimen, the KAI1 protein expression of the tumor was considered to be conserved, otherwise it was considered to be reduced. These judgments were made by two pathologists independently. Microsatellite analysis of loss of heterozygosity (LOH) or replication error (RER) DNA was isolated from each tumor tissue and its adjacent non-cancerous lung tissue by phenol-chloroform extraction. The polymorphic microsatellite markers D11S1326 and D11S1344 are located near the KAI1 gene. 18) The primer sequences used were 5′-TGCCAAGAACAGCAAAA-3′ (CA strand) and 5′-GGGGTTCAAAATAAACAAAA-3′ (GT strand) for D11S1326 and 5′-CCCTGAACTTCTGCATTCAC-3′ (CA strand) and 5′-GCGCCTGGCTTGTACATATA-3′ (GT strand) for D11S1344. PCR was carried out in a volume of 50 µl including 50 ng of genomic DNA, each primer at 0.5 µM, 0.25 mM deoxynucleotide triphosphate, 10 mM TrisHCl buffer (pH 8.3), 50 mM KCl, 1.5 mM MgCl 2 , 2 units of Taq polymerase and 5 µCi [α-32 P]dCTP. PCR was for 27 cycles of denaturation at 94°C for 40 s, annealing at 56°C for 60 s, and extension at 72°C for 120 s. The PCR products were separated by electrophoresis on a 6% polyacryl- amide gel. Autoradiography was for 1 day. Negative control reactions without DNA were carried out for each primer set and no product was detected (data not shown).
The radioactivity of the PCR products was compared between tumor and non-cancerous DNA in each case. We measured the intensity of the band amplified from each allele and used the intensity ratio of two alleles in noncancerous DNA as the control of heterozygosity. We diagnosed LOH only when the observed intensity of one allele in the tumor DNA was less than 50% of expected intensity, which was calculated from the control. Statistical analysis Statistical evaluations were performed using the χ 2 test. Correlations were regarded as significant when the P-value was less than 0.05.
RESULTS
Correlation between KAI1 mRNA expression and clinicopathological factors The quantitative RT-PCR assay
showed that 27 of 49 (55.1%) lung adenocarcinomas had conserved KAI1 mRNA expression (Fig. 2) . There was no correlation between KAI1 mRNA expression and patients' age or tumor size, though KAI1 mRNA expression did significantly correlate with gender (P=0.047), metastasis to the lymph nodes or other organs (P=0.004), the histological grade of the tumor (P=0.036) and the pathological stage (P=0.049) ( Table I ). The tumors of female patients showed conserved KAI1 mRNA expression more often than those of the male patients and KAI1 mRNA expression was also conserved more frequently in cases without metastasis compared to cases with metastasis. Furthermore, the well-differentiated adenocarcinomas had a higher frequency of conserved KAI1 mRNA expression than the moderately differentiated or poorly differentiated tumors. Similarly, there was a tendency for less advanced tumors to show conserved KAI1 expression more often than advanced cases. Immunohistochemical staining Of 49 adenocarcinomas, 24 (49%) showed conserved KAI1 protein expression (Figs. 3 and 4) . These results were generally consistent with the RT-PCR data. Case 6 was unusual because there was no metastasis to the lymph nodes or other organs even though both KAI1 mRNA expression and KAI1 protein expression were reduced. However, we observed histologically that KAI1 protein-negative adenocarcinoma cells had invaded the stroma in this specimen (Fig. 5) . Microsatellite analysis The numbers of informative cases were 14 of 49 (28.6%) examined cases at D11S1344 and 27 of 49 (55.1%) at D11S1326 (Fig. 6) . All informative Fig. 5 . Microscopic view of case 6, which had no metastasis clinicopathologically and had reduced KAI1 mRNA expression by RT-PCR assay. Serial sections were stained with hematoxylin and eosin (a) (×100) and anti-KAI1 antibody (b) (×200). Adenocarcinoma cells that expressed no KAI1 protein had invaded the stroma. Table II cases were grouped based on the conservation or reduction in KAI1 mRNA expression. None of the adenocarcinomas showed LOH or RERs in any case (Table II) .
DISCUSSION
Some kinds of cancer show down-regulation of KAI1 mRNA during the progression of tumors with metastatic ability, but the mechanism of this down-regulation has not been identified. Moreover, the involvement of KAI1 gene alterations in prostate cancer is controversial. Kawana et al. observed LOH or RERs at D11S1344 in 7 of 10 (70%) informative metastatic lesions and in 3 of 9 (33%) informative primary prostate tumors.
18) However, Dong et al. reported that LOH was never seen at the same locus (D11S1344) in 34 primary prostate tumors and 12 metastatic lesions. 19) Hence, the relevance of DNA alterations of the KAI1 gene region to metastasis is far from clear. Therefore we conducted microsatellite analysis in lung adenocarcinomas by using the markers D11S1344 and D11S1326, which are close to the KAI1 locus.
First, RT-PCR analysis was performed to identify each case as having conserved or reduced KAI1 mRNA expression in the tumor. We observed that KAI1 mRNA expression in the tumor was reduced more often in men than in women. This difference may be due to smoking, though the smoking index was not investigated in this study. Sex hormones also may influence KAI1 expression, but no evidence for this has been reported to date. We observed a strong negative correlation between metastasis and KAI1 mRNA expression; 70% of the carcinomas with metastasis had reduced KAI1 mRNA expression. This observation is in agreement with previous reports about several organic cancers. 11-13, 15, 16, 19, 20) In the present series, we observed that metastasis occurred more frequently in men than in women (P=0.045). It is possible that the significant correlation between gender and KAI1 mRNA expression might be related to the frequency of metastasis. It is unclear why 30% of the carcinomas with metastasis had normal KAI1 mRNA expression, although there are several possibilities to consider. First, these tumors may have decreased levels of proteins that up-regulate the function of KAI1, or increased levels of proteins that down-regulate the function of KAI1. Second, the three potential N-glycosylation sites of the KAI1 protein, which are thought to be associated with its role in metastasis suppression, may be dysfunctional. 10) By contrast, 28% of the carcinomas without metastasis showed reduced KAI1 mRNA expression. Interestingly, in case 6, adenocarcinoma cells that expressed no KAI1 protein had invaded the stroma but not the lymph nodes or other organs. Hence, when KAI1 protein expression is reduced in cancer cells, microinvasion may occur even when there is no spread to distant sites. So far, the precise role of KAI1 is not understood, but like the other members of the transmembrane 4 superfamily, KAI1 protein may play a role in cell-cell interactions, which are important in invasion and metastasis. The immunohistochemical staining result of case 6 is consistent with this hypothesis. Indeed, in a recent study on breast carcinoma cell lines, low expression of KAI1 mRNA was associated with high metastatic propensity and invasive ability.
14) It has also been reported that after gene transfer to induce the reexpression of KAI1 protein in highly metastatic rat prostate cancer cells, colon cancer cells and melanoma cells, these cells showed reduced invasiveness and motility. 3, 16, 21) These reports suggest that KAI1 protein is an invasion-suppressor glycoprotein. We observed that well-differentiated adenocarcinomas had conserved KAI1 mRNA expression more frequently than moderately or poorly differentiated adenocarcinomas. Although the factors that determine the degree of differentiation have not been identified so far, KAI1 protein may influence the differentiation of cancer cells. We analyzed the relationship between the histological grade of the tumor and metastasis, but found no correlation (P=0.481). Thus, histological grade and metastasis were considered to be independent factors for KAI1 mRNA expression.
Our microsatellite analysis detected no LOH or RERs in any of 49 primary lung tumors at D11S1344 and D11S1326. By contrast, Kawana et al. 18) observed LOH or RERs at D11S1344 in 7 of 10 (70%) informative metastatic lesions, in 3 of 9 (33%) informative primary prostate tumors and in 1 of 12 (8%) informative clinically localized prostate tumors. However, there are some technical differences between our study and theirs. First, they grouped their specimens into localized tumors, primary carcinomas with metastasis and metastatic lesions, whereas we grouped our specimens based on the conservation or reduction in KAI1 mRNA expression because microinvasion may occur even if there is no metastasis. Second, we did not analyze metastatic lesions. Usually, the cancer cells of a metastatic lesion are at a more advanced stage than those of the primary tumor. Indeed, Higashiyama et al. reported that the KAI1 protein expression levels in metastatic lesions were diminished compared with levels of expression in the primary lung lesions. 12) Consequently, the results of our study suggest that down-regulation of KAI1 mRNA expression rarely involves loss of heterozygosity or replication errors near the KAI1 gene in primary lung adenocarcinoma.
Recently, it was reported that several CpG-rich islands are present in the 5′ promoter region of the KAI1 gene, so methylation may be associated with the down-regulation of KAI1 mRNA. 19, 22) It has also been suggested that the loss of p53 function may lead to down-regulation of KAI1 gene expression. 23) In the light of these findings further investigations are necessary to identify the mechanisms of down-regulation of KAI1.
